NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ultragenyx Pharmaceutical Inc. RARE
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$673.0M
▲ 20.2% vs FY2024
EPS · FY25
$-5.83
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-657.1%
Net margin · FY25
-85.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 673.0M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 85 cents on every revenue dollar this year.
Per share
USD -5.83
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-657.1%
Return on equity, FY2025
ROE
Operating margin-79.5%
Net margin-85.4%
Return on assets-37.9%
Each USD of equity lost 657 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+19.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+22.8%
+19.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+44.6%
Change, 10 years+148.4%
The share count grew 45% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.5B
total assets, end of FY2025
Total assetsUSD 1.5B
EquityUSD -80.0M
CashUSD 421.0M
Current ratio2.48×
Equity funds -5% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.7
0.6
0.4
0.4
0.4
0.3
0.1
0.1
0.0
0.0
·
·
·
·
Operating income $B
−0.5
−0.5
−0.6
−0.6
−0.4
−0.3
−0.4
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.5
−0.5
−0.5
−0.6
−0.4
−0.3
−0.4
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.6
−0.6
−0.6
−0.7
−0.5
−0.2
−0.4
−0.2
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−5.83
−6.29
−8.25
−10.12
−6.70
−3.07
−7.12
−3.97
−7.12
−6.21
−3.96
−2.25
−14.87
−14.20
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
0.00
0.00
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−657.1
−214.7
−193.6
−111.0
−43.7
−20.6
−63.8
−39.8
−70.5
−48.9
−40.7
−108.6
·
·
Shares out B
0.10
0.09
0.08
0.07
0.07
0.07
0.06
0.05
0.04
0.04
0.04
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
38 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed